Description
Ruxolitinib, like other JAK inhibitors, carries an FDA boxed warning for serious infections, increased all-cause mortality, malignancy, major cardiovascular events, and thrombosis. Discuss your individual risk factors with your haematologist before starting.
Is Ruxotor 10 mg right for your situation?
Review these criteria with your haematologist before enquiring- ✓Intermediate or high-risk myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia)
- ✓Polycythemia vera with inadequate response to hydroxyurea
- ✓Steroid-refractory acute graft-versus-host disease, per specialist protocol
- ✓Need a WHO-GMP generic alternative to Jakafi® (Incyte)
- ✗Platelet count below 50 x 10⁹/L without close monitoring
- ✗Active serious infection
- ✗Pregnant, planning pregnancy, or breastfeeding
- ✗Significant hepatic or renal impairment without dose adjustment
Check Availability & Pricing
Prescription required · Named Patient Program · Worldwide shipping
🛡 WHO-GMP Certified · Prescription verified · Express dispatch
What is Ruxotor 10 mg?
Ruxotor 10 mg is a generic formulation of Ruxolitinib — an oral JAK1/JAK2 inhibitor — manufactured by Everest Pharmaceuticals Ltd. under WHO-GMP certified conditions in Bangladesh. Each tablet contains 10 mg of ruxolitinib, the same active molecule found in Jakafi® (Incyte), and is dispensed under the Named Patient Program.
Ruxolitinib was the first FDA-approved treatment specifically for myelofibrosis, receiving approval in 2011. It remains a foundational therapy for this and related myeloproliferative conditions.
| Generic name | Ruxolitinib |
| Reference brand | Jakafi® (Incyte) |
| Manufacturer | Everest Pharmaceuticals Ltd. |
| Standard | WHO-GMP Certified |
| Drug class | JAK1/JAK2 Inhibitor |
| Dosage form | Tablet — 10 mg |
| Pack size | 60 tablets per pack |
| Route | Oral · twice daily, with or without food |
| Prescription | Required — haematologist/oncologist only |
How Ruxolitinib Works
Myelofibrosis and related myeloproliferative disorders are driven by overactive JAK1 and JAK2 signalling, which causes abnormal bone marrow cell production, inflammation, and progressive scarring of the bone marrow.
Dosing by Platelet Count
Ruxolitinib dosing for myelofibrosis is determined by your baseline platelet count — your haematologist will select the correct starting dose from this table.
| Platelet count >200 × 10⁹/L | 20 mg twice daily (starting dose) |
| Platelet count 100–200 × 10⁹/L | 15 mg twice daily (starting dose) |
| Platelet count 50–100 × 10⁹/L | 5 mg twice daily, with caution |
| Maximum dose | 25 mg twice daily |
Complete blood counts (CBC) are checked every 2–4 weeks until doses are stabilised, and periodically thereafter.
Side Effects
Common · Usually Manageable
- Dizziness, headache
- Bruising
- Fatigue
- Nausea
- Diarrhoea
Serious · Report Immediately
- Thrombocytopenia (low platelets)
- Anaemia, neutropenia
- Serious infections
- Herpes zoster reactivation
- Thrombosis
- Fever, chills, or signs of infection
- Unusual bruising, bleeding, or petechiae
- Sudden leg swelling/pain, chest pain, or breathlessness
How to Take Ruxotor 10 mg
- 1Twice daily, with or without food — at the dose your haematologist has determined based on your platelet count.
- 2Swallow tablet whole with water, or if unable to swallow, your pharmacist can advise on suspension in water for immediate use only.
- 3Avoid grapefruit and grapefruit juice — this can significantly increase ruxolitinib blood levels via CYP3A4 interaction.
- 4If you miss a dose, do not double up — take your next regular dose at the scheduled time.
- 5On dialysis: take Ruxotor after your dialysis session, as specifically directed by your nephrologist and haematologist.
- 6Storage: dry place, room temperature, out of reach of children and pets.
Frequently Asked Questions
Is Ruxotor a biosimilar?
Why is my starting dose based on platelet count?
Why should I avoid grapefruit?
How do I order Ruxotor through Meds For Cancer?
Meds For Cancer operates as a Named Patient Program (NPP) facilitator. WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid prescription, in countries where the branded product is unavailable or unaffordable.
- Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis (COMFORT-I). NEJM 2012;366:799–807.
- FDA Prescribing Information: Jakafi (ruxolitinib), including Boxed Warning. Incyte, 2023.
Reviews
There are no reviews yet.